1 / 57

Management of Hypertension: An Overview & Update

Management of Hypertension: An Overview & Update. 11/12/11 Marcus Weiser, DO PGY3 Chief Resident Via Christi Family Medicine. Outline. Classification Causes History, PE, initial testing Antihypertensive agents Monotherapy & combination therapy. Hypertension.

orea
Download Presentation

Management of Hypertension: An Overview & Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Management of Hypertension:An Overview & Update 11/12/11 Marcus Weiser, DO PGY3 Chief Resident Via Christi Family Medicine

  2. Outline • Classification • Causes • History, PE, initial testing • Antihypertensive agents • Monotherapy & combination therapy

  3. Hypertension • Sustained elevation of arterial systemic blood pressure • Single most common diagnosis at US family physician office visits (coded at 11.1%) • Age 20-50 usually affected • 29% of US adults • Prevalence increases with age

  4. Hypertension • Baseline high blood pressure at age 50 reduces life expectancy by about 5 years.1 • Associations • Erectile dysfunction, ophthalmologic conditions, osteoporosis, anxiety, chronic kidney disease, obstructive sleep apnea, coronary artery disease, cerebrovascular disease, peripheral arterial disease, congestive heart failure, dementia

  5. Types • Prehypertension (SBP 120-139 or DBP 80-89) • Stage I (SBP 140-159 or DBP 90-99) • Confirm within 2 months • Stage II (SBP > 159 or DBP > 99) • Evaluate within 1 month (within 1 week if > 180/110) • Type I (vasoconstriction, high renin, high SBP) • Treat with ACE, ARB, BB • Type II (Na dependent, low renin, high DBP) • Treat with diuretics, CCB

  6. ICD-10 codes • I10 essential (primary) hypertension • ICD-10-CA modification in Canada • I10.0 benign hypertension • I10.1 malignant hypertension • I11 hypertensive heart disease • I11.0 hypertensive heart disease with (congestive) heart failure • I11.9 hypertensive heart disease without (congestive) heart failure • ICD-10-CA modification in Canada - 4th character extensions were deleted to allow for use of dual classification for added specificity • I12 hypertensive renal disease • I12.0 hypertensive renal disease with renal failure • I12.9 hypertensive renal disease without renal failure • ICD-10-CA modification in Canada - 4th character extensions were deleted to allow for use of dual classification for added specificity • I13 hypertensive heart and renal disease • I13.0 hypertensive heart and renal disease with (congestive) heart failure • I13.1 hypertensive heart and renal disease with renal failure • I13.2 hypertensive heart and renal disease with both (congestive) heart failure and renal failure • I13.9 hypertensive heart and renal disease, unspecified • ICD-10-CA modification in Canada - 4th character extensions were deleted to allow for use of dual classification for added specificity • I15 secondary hypertension • I15.0 renovascular hypertension • I15.1 hypertension secondary to other renal disorders • I15.2 hypertension secondary to endocrine disorders • I15.8 other secondary hypertension • I15.9 secondary hypertension, unspecified • ICD-10-CA modification in Canada • 5th digits assigned to specify • 0 benign or unspecified • 1 malignant • R03.0 elevated blood-pressure reading, without diagnosis of hypertension

  7. CKD (any cause) Renal Artery Stenosis Cushing Syndrome Primary Hyperaldosteronism Hyper/Hypothyroidism Hyperparathyroidism Pheochromocytoma Obstructive Sleep Apnea Coarctation of the Aorta Black Licorice Medications BP Cuff too small Arm position Caffeine Nicotine Substance Abuse/Intoxication Short sleep duration Alcohol Use Salt intake? Impatience, hostility Causes

  8. History • Symptoms • Medications • Corticosteroids, OCPs, NSAIDs, venlafaxine, buspirone, carbamazepine, clozapine, bromocriptine, cyclosporin, tacrolimus, EPO • Past Medical History • DM, CAD, CHF, DSLD, Thyroid/Renal Dz • Social History • Dietary sodium, stress, smoking, alcohol intake, activity level, St. John’s wort, ergot-containing herbal preparations, cocaine, anabolic steroids, narcotic withdrawal, meth, PCP

  9. Physical Exam • Proper blood pressure measurement • Seated in chair with back in calm, quiet, warm room for at least 5 minutes. Bare arm elevated so elbow is level with heart. No smoking or caffeine 1 hour prior • Cuff width > 2/3 arm diameter • Cuff length > 2/3 arm circumference • Average of 2 measurements • Carotid bruits • Cardiac auscultation • Abdomen • Extremities

  10. Serum Potassium Serum Creatinine Fasting Blood Glucose Fasting Lipid Panel Urinalysis Electrocardiogram - Uniformly recommended by 4 expert panels (CHEP, ESH/ESC, ICSI, JNC7) Hematocrit Serum Calcium Serum Sodium Serum Uric Acid Urine Albumin/Creatinine Ratio - Recommended by some, not all 4 panels Initial Testing

  11. Additional Testing to Consider • PTH • TSH • 24 hour urine metanephrine • Plasma Aldosterone • Plasma Renin • Dexamethasone supression test • Sleep study • RAS imaging

  12. Agents • Ace-inhibitors (ACEs) • Angiotensin Receptor Blockers (ARBs) • Calcium Channel Blockers (CCBs) • Beta Blockers (BBs) • Thiazide Diuretics (TZD) • Loop Diuretics (Loops) • Aldosterone Antagonists • Alpha Blockers • Other agents

  13. ACEs & ARBs • Special Indications • ACE • CHF (SOLVD, AIRE, TRACE) • Post-MI (SAVE) • Diabetes (UKPDS, HOPE) • CKD (REIN, AASK, CAPTOPRIL) • Recurrent Stroke Prevention (PROGRESS) • High CAD Risk (ALLHAT, HOPE, ANBP2) • ARB • CHF (Val-HeFT) • Diabetes • CKD (RENAAL, IDNT, CAPTOPRIL)

  14. ACEs & ARBs • Contraindications • Pregnancy, Angioedema, Renovascular Disease, Hyperkalemia, Acute Renal Failure • Monitor • Creatinine, Potassium • Agents • Benazepril or Lisinopril (20mg to 40mg PO daily) • Enalapril, Ramipril • Losartan, Olmesartan, Valsartan

  15. Calcium Channel Blockers • Special Indications • High CAD risk (ALLHAT, CONVINCE) • Migraines • Raynaud’s • Angina (non-dihydropyridine) • Atrial Fibrillation (non-dihydropyridine) • Atrial Flutter (non-dihydropyridine)

  16. Calcium Channel Blockers • Contraindications • 2nd or 3rd degree heart block • Agents • Amlodipine (5mg to 10mg PO daily) • Nifedipine, Nicardipine, Felodipine

  17. Beta Blockers • Special Indications • CHF (MERIT-HF, COPERNICUS, CIBIS) • Post-MI (BHAT, CAPRICORN) • Angina, Atrial Fibrillation, Atrial Flutter, Tremor, Migraine • Contraindications • Asthma, COPD, 2nd or 3rd degree heart block, Depression, Acute CHF • Avoid abrupt cessation • Agents • Metoprolol (50mg to 200mg PO BID) • Carvedilol (3.125mg to 25mg PO BID) • Atenolol, Nebivolol, Labetalol, Esmolol, Propranolol, Timolol

  18. Beta BlockersInappropriate first-line treatment • JNC8 • Worse BP control (LIFE) • Worse CV outcome prevention (LIFE) • Increased mortality (ASCOT) • Higher risk of stroke 2 • More side effects 2 • Increased risk of type II diabetes 3

  19. Thiazide Diuretics • Special Indications • High CAD risk (ALLHAT) • Recurrent stroke prevention (PROGRESS) • DM without proteinuria (ALLHAT) • Edema • Osteoporosis

  20. Thiazide Diuretics • Contraindications • Stage IV CKD, Gout, Hyponatremia, Acute Renal Failure • Monitor • Creatinine, Potassium, Sodium • Agents • Chlorthalidone (12.5mg to 25mg PO daily) • Hydrochlorothiazide, Indapamide, Metolazone

  21. Thiazide equivalence? • Chlorthalidone vs HCTZ • Chlorthalidone use has sharply declined over the last 20 years for reasons unknown 4

  22. ACCOMPLISH

  23. Chlorthalidone vs HCTZ • Amlodipine appears superior to HCTZ

  24. ALLHAT • Secondary Outcome

  25. Chlorthalidone vs HCTZ • Amlodipine appears superior to HCTZ • Chlorthalidone appears superior to Amlodipine

  26. ALLHAT • Secondary Outcome • Lower rate of combined CVD with Chlorthalidone

  27. Chlorthalidone vs HCTZ • Amlodipine appears superior to HCTZ • Chlorthalidone appears superior to Amlodipine • Chlorthalidone appears superior to Lisinopril

  28. ACE-I Beats Diuretic (ANBP2) • Rate of events per year

  29. Chlorthalidone vs HCTZ • Amlodipine appears superior to HCTZ • Chlorthalidone appears superior to Amlodipine • Chlorthalidone appears superior to Lisinopril • Enalapril appears superior to HCTZ

  30. Thiazide equivalence? • Chlorthalidone vs HCTZ • Chlorthalidone use has sharply declined over the last 20 years for reasons unknown 4 • No evidence that HCTZ improves cardiovascular outcomes • Large body of evidence in major trials (ALLHAT) showing cardiovascular event reduction and outcome benefit with chlorthalidone • Chlorthalidone has much longer half-life, is 1.5-2.0 times more potent, and has slightly more hypokalemia (7-8% patients require treatment 5,6)

  31. Thiazide Diuretics • Chlorthalidone superior reduction of nighttime BP, compared to HCTZ 7 • 13.5 mmHg vs 6.4 mmHg • Chlorthalidone (12.5-25mg) vs HCTZ (25-50mg) • Agents • Chlorthalidone (12.5mg to 25mg PO daily) • Hydrochlorothiazide, Indapamide, Metolazone

  32. Loop Diuretics • Special Indications • CHF, Edema • Contraindications • Gout, Acute Renal Failure • Monitor • Creatinine, Electrolytes • Agents • Torsemide (5mg to 10mg PO daily) • Furosemide, Bumetanide

  33. Aldosterone Antagonists • Special Indications • CHF (RALES) • Post-MI (EPHESUS) • Contraindications • Gout, Hyperkalemia, Acute Renal Failure • Monitor • Creatinine, Potassium • Agents (ASCOT) • Spironolactone (25mg to 50mg once daily) • Amiloride, Triamterene

  34. ASCOT • Patients with uncontrolled hypertension on 3 antihypertensive agents • Spironolactone 25mg once daily added as 4th agent • Mean BP drop of 22/10 at one year follow-up

  35. Alpha Blockers • Special Indications • BPH • Contraindications • High CV risk (ALLHAT) • Agents • Doxazosin, Prazosin, Terazosin

  36. Other Agents • Clonidine • Methyldopa • Hydralazine • Tekturna • Minoxidil • Isosorbide dinitrate/mononitrate

  37. Low . . . but how low is too low? • Treatment goal < 140/90 • < 130/80 in diabetics per JNC7 recommendation • ACCORD, INVEST • BP targets below 140/90 overall do not improve morbidity or mortality • DBP < 70 increases risk of death, MI, stroke

  38. Lifestyle ModificationsFirst-Line Treatment • Sodium Restriction (2-8 mmHg) • DASH (8-14 mmHg) • Fruits, vegetables, low-fat dairy, reduced fat • Aerobic physical activity (4-9 mmHg) • Weight Reduction • (5-20 mmHg per 10 kg lost) • Moderate alcohol (2-4 mmHg) • Smoking Cessation *From JNC7 Express Report, 2003

  39. Sequential treatment Avoid excessive dosing First-line agents Avoid similar agents Avoid excessive dosing Other agents Monotherapy vs Multi-Drug Therapy

  40. Monotherapy – 1st line agents • 1. Thiazide • Chlorthalidone 12.5mg daily, titrate to 25mg? • 2. ACE/ARB • Benazepril or Lisinopril 20mg daily • Titrate up to 40mg, possibly beyond • 3. Calcium Channel Blocker (dihydropyridine) • Amlodipine 5mg daily • Titrate up to 10mg once daily

  41. Monotherapy • Sequential treatment • Try one agent, titrate up • If inadequate control, switch instead of add • Each first-line agent will normalize BP in 30-50% of patients 8,9 • 49.1% chance a different agent will control Stage I Hypertension following failure of initial agent 10 • May prevent unnecessary multi-drug treatment • JNC7 recommendation for uncontrolled stage I hypertension on monotherapy is to optimize dose or add 2nd medication • Addition of a second drug from a different class should be initiated when use of a single drug in adequate doses fails to achieve the BP goal

  42. Combination Therapy • Consider combination for Stage 2 • Add if sequential monotherapy fails • Drugs for each compelling indication • ACCOMPLISH • Include a diuretic • Consider Spironolactone as 4th agent (ASCOT) • First-line agents

  43. ACCOMPLISH

  44. ACCOMPLISH

  45. ACCOMPLISH

  46. Combination Therapy • Drugs for each compelling indication • ACCOMPLISH • Include a diuretic • First-line agents • Consider Spironolactone as 4th agent (ASCOT)

  47. Resistant Hypertension • Uncontrolled on 3 medications • Controlled on 4 or more medications • Must include a diuretic

  48. CKD (any cause) Renal Artery Stenosis Cushing Syndrome Primary Hyperaldosteronism Hyper/Hypothyroidism Hyperparathyroidism Pheochromocytoma Obstructive Sleep Apnea Coarctation of the Aorta Licorice Medications BP Cuff too small Arm position Caffeine Nicotine Substance Abuse/Intoxication Short sleep duration Alcohol Use Salt intake? Impatience, hostility Causes

More Related